Literature DB >> 29889562

Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Nikki A Thiele1, Justin J Wilson1.   

Abstract

The α-emitting radionuclide actinium-225 possesses nuclear properties that are highly promising for use in targeted α therapy (TAT), a therapeutic strategy that employs α particle emissions to destroy tumors. A key factor, however, that may hinder the clinical use of actinium-225 is the poor understanding of its coordination chemistry, which creates challenges for the development of suitable chelation strategies for this ion. In this article, we provide an overview of the known chemistry of actinium and a summary of the chelating agents that have been explored for use in actinium-225-based TAT. This overview provides a starting point for researchers in the field of TAT to gain an understanding of this valuable therapeutic radionuclide.

Entities:  

Keywords:  actinides; actinium-225; coordination chemistry; macrocyclic ligands; radiopharmaceuticals; targeted α therapy

Mesh:

Substances:

Year:  2018        PMID: 29889562      PMCID: PMC6207149          DOI: 10.1089/cbr.2018.2494

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  64 in total

1.  Improved 225Ac daughter retention in InPO4 containing polymersomes.

Authors:  R M de Kruijff; K Drost; L Thijssen; A Morgenstern; F Bruchertseifer; D Lathouwers; H T Wolterbeek; A G Denkova
Journal:  Appl Radiat Isot       Date:  2017-07-16       Impact factor: 1.513

2.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

Authors:  T K Nikula; M R McDevitt; R D Finn; C Wu; R W Kozak; K Garmestani; M W Brechbiel; M J Curcio; C G Pippin; L Tiffany-Jones; M W Geerlings; C Apostolidis; R Molinet; M W Geerlings; O A Gansow; D A Scheinberg
Journal:  J Nucl Med       Date:  1999-01       Impact factor: 10.057

Review 3.  Targeted radionuclide therapy--an overview.

Authors:  Ashutosh Dash; F F Russ Knapp; M R A Pillai
Journal:  Curr Radiopharm       Date:  2013-09

4.  Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.

Authors:  Justin J Wilson; Maryline Ferrier; Valery Radchenko; Joel R Maassen; Jonathan W Engle; Enrique R Batista; Richard L Martin; Francois M Nortier; Michael E Fassbender; Kevin D John; Eva R Birnbaum
Journal:  Nucl Med Biol       Date:  2014-12-20       Impact factor: 2.408

Review 5.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

6.  Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer.

Authors:  Marek Pruszynski; Matthias D'Huyvetter; Frank Bruchertseifer; Alfred Morgenstern; Tony Lahoutte
Journal:  Mol Pharm       Date:  2018-03-07       Impact factor: 4.939

7.  Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.

Authors:  Markus Essler; Florian C Gärtner; Frauke Neff; Birgit Blechert; Reingard Senekowitsch-Schmidtke; Frank Bruchertseifer; Alfred Morgenstern; Christof Seidl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-12       Impact factor: 9.236

8.  Density functional theory studies of actinide(III) motexafins (An-Motex2+, An = Ac, Cm, Lr). Structure, stability, and comparison with lanthanide(III) motexafins.

Authors:  Xiaoyan Cao; Quansong Li; Anna Moritz; Zhizhong Xie; Michael Dolg; Xuebo Chen; Weihai Fang
Journal:  Inorg Chem       Date:  2006-04-17       Impact factor: 5.165

Review 9.  Targeting of radio-isotopes for cancer therapy.

Authors:  Diane E Milenic; Martin W Brechbiel
Journal:  Cancer Biol Ther       Date:  2004-04-03       Impact factor: 4.742

10.  Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Authors:  Matthias Miederer; Michael R McDevitt; George Sgouros; Kim Kramer; Nai-Kong V Cheung; David A Scheinberg
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

View more
  19 in total

1.  Melanocortin 1 Receptor-Targeted α-Particle Therapy for Metastatic Uveal Melanoma.

Authors:  Narges K Tafreshi; Christopher J Tichacek; Darpan N Pandya; Michael L Doligalski; Mikalai M Budzevich; HyunJoo Kil; Nikunj B Bhatt; Nancy D Kock; Jane L Messina; Epifanio E Ruiz; Nella C Delva; Adam Weaver; William R Gibbons; David C Boulware; Nikhil I Khushalani; Ghassan El-Haddad; Pierre L Triozzi; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse
Journal:  J Nucl Med       Date:  2019-02-07       Impact factor: 10.057

2.  H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy.

Authors:  Karthika J Kadassery; A Paden King; Stanley Fayn; Kwamena E Baidoo; Samantha N MacMillan; Freddy E Escorcia; Justin J Wilson
Journal:  Bioconjug Chem       Date:  2022-06-07       Impact factor: 6.069

3.  Polyoxometalates as ligands to synthesize, isolate and characterize compounds of rare isotopes on the microgram scale.

Authors:  Ian Colliard; Jonathan R I Lee; Christopher A Colla; Harris E Mason; April M Sawvel; Mavrik Zavarin; May Nyman; Gauthier J-P Deblonde
Journal:  Nat Chem       Date:  2022-09-01       Impact factor: 24.274

4.  Stable Chelation of the Uranyl Ion by Acyclic Hexadentate Ligands: Potential Applications for 230U Targeted α-Therapy.

Authors:  Joshua J Woods; Ryan Unnerstall; Abbie Hasson; Diane S Abou; Valery Radchenko; Daniel L J Thorek; Justin J Wilson
Journal:  Inorg Chem       Date:  2022-02-09       Impact factor: 5.436

5.  Rapid Dissolution of BaSO4 by Macropa, an 18-Membered Macrocycle with High Affinity for Ba2.

Authors:  Nikki A Thiele; Samantha N MacMillan; Justin J Wilson
Journal:  J Am Chem Soc       Date:  2018-11-28       Impact factor: 15.419

Review 6.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

Review 7.  Perspectives on metals-based radioimmunotherapy (RIT): moving forward.

Authors:  Jordan M White; Freddy E Escorcia; Nerissa T Viola
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

8.  Theoretical Study of Actinide(III)-DOTA Complexes.

Authors:  Attila Kovács
Journal:  ACS Omega       Date:  2021-05-11

9.  Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review.

Authors:  Hua Yang; Justin J Wilson; Chris Orvig; Yawen Li; D Scott Wilbur; Caterina F Ramogida; Valery Radchenko; Paul Schaffer
Journal:  J Nucl Med       Date:  2021-09-09       Impact factor: 11.082

10.  Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC.

Authors:  Eline L Hooijman; Yozlem Chalashkan; Sui Wai Ling; Figen F Kahyargil; Marcel Segbers; Frank Bruchertseifer; Alfred Morgenstern; Yann Seimbille; Stijn L W Koolen; Tessa Brabander; Erik de Blois
Journal:  Pharmaceutics       Date:  2021-05-13       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.